An analysis published in 2020, and including indirect costs, estimated that the total annual economic cost of PD will exceed $79 billion by 2037 in the US alone.1
Some analyses show that the prevalence of PD is increasing beyond what would be expected based purely on population growth, leading some to call for action on the so-called PD pandemic.2
Related content
Overview of three therapeutic strategies targeting alpha-synuclein in the development of disease-modifying treatments for Parkinson’s disease
Graphical representation of how various treatment strategies can impact disease progression in Parkinson’s disease, from symptom relief to potential cure
Illustration of how COMT inhibitors increase dopamine availability in Parkinson’s disease by preventing the breakdown of L-DOPA